Angiotensin receptor blockers in nephroprotection at patients with diabetes mellitus: focus on losartan

• Main Authors: Ol'ga Konstantinovna Vikulova, Marina Vladimirovna Shestakova
• Format: Article
• Language: Russian
• Published: IP Morozov P.V. 2009-09-01
• Series: Системные гипертензии
• Subjects: nephroprotection; diabetes mellitus; losartan
• Online Access: https://syst-hypertension.ru/2075-082X/article/view/33072

Many large studies have provided strong evidence that there is an association of elevated BP with a risk for cardiovascular events (CVE), such as stroke, myocardial infarction and heart failure. But none of the studies has indicated that a drug is more effective than another one in reducing the risk for CVE and death. The article summarizes the available data on ramipril in hypertensive patients of high cardiovascular risk. The results of studies demonstrate strong and long-lasting antihypertensive effect of losartan. Moreover, losartan treatment decreases cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. Losartan shows both high efficacy and low adverse event rate.